Tag: Antibiotics

Antibiotics, also called antibacterials, are a type of antimicrobial drug used in the treatment and prevention of bacterial infections. They may either kill or inhibit the growth of bacteria. A limited number of antibiotics also possess antiprotozoal activity. Antibiotics are not effective against viruses such as the common cold or influenza, and their inappropriate use allows the emergence of resistant organisms. Drugs which inhibit viruses are termed antiviral drugs or antivirals rather than antibiotics.
Sometimes the term antibiotic (which means “opposing life”) is used to refer to any substance used against microbes, synonymous with antimicrobial. Some sources distinguish between antibacterial and antibiotic; antibacterials are used in soaps and disinfectants, while antibiotics are used as medicine. Antibiotics revolutionized medicine in the 20th century, and have together with vaccination led to the near eradication of diseases such as tuberculosis in the developed world. However, their effectiveness and easy access led to overuse, especially in livestock raising, prompting bacteria to develop resistance. This has led to widespread problems with antimicrobial and antibiotic resistance, so much as to prompt the World Health Organization to classify antimicrobial resistance as a “serious threat [that] is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country”. All classes of antibiotics in use today were first discovered prior to the mid 1980s.

Boston College researchers made a step towards targeted antibiotics

The approach of Boston College scientists maps, ranks, and identifies where antibiotic sensitivity functions reside in the genome of strains of S. pneumoniae.

A study on prevalence of antibiotic resistance was conducted in Russia

Antimicrobial resistance
GSK published the results of its Survey of Antibiotic Resistance in Russia. The collected data revealed high sensitivity of the main bacteria causing respiratory infections to amoxicillin/clavulanate and fluoroquinolones.

Russia may simplify registration of new antibiotics

This was announced by Sergey Glagolev, the Head of the Division for Monitoring the Efficacy and Safety of Medical Products, the Department of the State Quality Control of Medical Products of Roszdravnadzor.

Russian developers of new antibiotics will be subsidized by the government

Russian companies are actively investing and working on new generation antibiotics. The Deputy Minister of Industry and Trade said that the development of new antibiotics is a priority project for the Ministry.

EMA will hold its second public hearing on antibiotics usage

The public hearing will give a voice to patients, doctors, nurses, pharmacists, researchers and everyone else who wants to share experience with quinolones and fluoroquinolones, a class of antibiotics widely prescribed in the EU.

Symcel starts collaboration with Karolinska Institutet

microbiology plates
Symcel, developer of the revolutionary cell-based assay tool for real-time cell metabolism measurements, partnered with the Karolinska Institutet in a Horizon 2020 funded project.

Kurgan-based Sintez is the leading manufacturer of antibiotics in Russia

sintez kurgan
In 2017, Sintez pharmaceutical plant once again became a leader in the Russian market of antibiotics by producing more than 32 million packages of antibacterial agents, or 23% of the total antibiotics manufactured in Russia.

Scientists distinguished a new class of antibiotics

A team of researchers led by Brown University infectious disease experts and engineers has identified a new class of antibiotics that could one day help combat the alarming emergence of drug-resistant “superbugs.”

The Dutch regulator is alarmed by antibiotics problem

The Dutch regulator has raised concerns about a shortage of narrow-spectrum antibiotics. A lack of targeted therapies is forcing doctors to use broad-spectrum antibiotics that increase the risk of antimicrobial resistance.

Nabriva Therapeutics and Roivant Sciences entered into license agreement

Nabriva Therapeutics, a clinical stage biopharmaceutical company, and Roivant Sciences, announced the initiation of a collaboration to develop and commercialize lefamulin

French biotech DEINOVE entered a license agreement with Redx Pharma

microbiology plates
DEINOVE, a French biotech company that discovers, develops, and produces high-value compounds from rare bacteria, signed a license option agreement with the British drug discovery company Redx Pharma.

Biokhimik launches full-cycle manufacturing of antibiotics

For the first time in a quarter of century, Russia launched the full-cycle manufacturing of antibiotics based exclusively on domestic components.

FDA published its updated Guidance on Systemic Antibacterial Drugs

The purpose of this guidance is to assist sponsors in the development, analysis, and presentation of microbiology data during antibacterial drug development.

WHO published new insights on antibiotic resistance

antimicrobial resistance
WHO’s first release of surveillance data on antibiotic resistance reveals high levels of resistance to a number of serious bacterial infections in both high- and low-income countries

The University of Geneva and AstraZeneca manage a new research project

microbiology plates
The research project DRIVE-AB has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years

Biokhimik will begin to produce more than 20 latest-generation antibiotics

manufacturing at biokhimik
The development of Biokhimik plant was discussed during the meeting between the Head of the Republic of Mordovia and the Chairman of the Board of Directors of Promomed Company